Report Detail
Global Infantile Spasms Therapeutics Market Growth 2019-2024
- RnM3002217 |
- 22 February, 2019 |
- Global |
- 130 Pages |
- LPI(LP Information) |
- Pharma & Healthcare
An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.
The global infantile spasms therapeutics market is growing at a slow pace. This is due to the increased availability of generic drugs and less approved therapies in the market and the less awareness of the disease and the available treatment options, especially in the low- and middle-income countries.
The classification of Infantile Spasms Therapeutics includes Oral, Injection. The proportion of Injection in 2016 is about 45%, and the proportion of Oral in 2016 is about 55%.
Based on application, the nitinol medical devices market is segmented into Hospital, Clinic and others. Clinic segment accounted for larger market share in terms of sales in 2016, Clinic segmented accounted for more than 45% of the market share in 2016.
United States is the largest consumption place, with a consumption market share nearly 83% in 2016. Following United States, Europe is the second largest consumption place with the consumption market share of 12.6% in 2016.
The US market is dominated by two approved products H.P. Acthar Gel (adrenocorticotropin hormone) and Sabril (vigabatrin). Sabril was the first drug to be approved by the Food and Drug Administration (FDA) in 2009 and H.P. Acthar Gel (adrenocorticotropin hormone) was approved for infantile spasms in 2010. Both have Orphan Drug Exclusivity (ODE) in the US.
In the future, the Infantile Spasms Therapeutics will have a good future; the price fluctuation has relationship with the raw material. The technology will more mature and the industry is more dispersion.
According to this study, over the next five years the Infantile Spasms Therapeutics market will register a 3.0% CAGR in terms of revenue, the global market size will reach US$ 150 million by 2024, from US$ 130 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Infantile Spasms Therapeutics business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Infantile Spasms Therapeutics market by product type, application, key manufacturers and key regions and countries.
This study considers the Infantile Spasms Therapeutics value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Oral
Injection
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Clinic
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Mallinckrodt
H. Lundbeck
Insys Therapeutics
Orphelia Pharma
Valerion Therapeutics
Catalyst Pharmaceuticals
Anavex Life Sciences
Retrophin
GW Pharmaceuticals
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Infantile Spasms Therapeutics consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Infantile Spasms Therapeutics market by identifying its various subsegments.
Focuses on the key global Infantile Spasms Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Infantile Spasms Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Infantile Spasms Therapeutics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2019-2024 Global Infantile Spasms Therapeutics Consumption Market Report
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Infantile Spasms Therapeutics Consumption 2014-2024
- 2.1.2 Infantile Spasms Therapeutics Consumption CAGR by Region
- 2.2 Infantile Spasms Therapeutics Segment by Type
- 2.2.1 Oral
- 2.2.2 Injection
- 2.3 Infantile Spasms Therapeutics Consumption by Type
- 2.3.1 Global Infantile Spasms Therapeutics Consumption Market Share by Type (2014-2019)
- 2.3.2 Global Infantile Spasms Therapeutics Revenue and Market Share by Type (2014-2019)
- 2.3.3 Global Infantile Spasms Therapeutics Sale Price by Type (2014-2019)
- 2.4 Infantile Spasms Therapeutics Segment by Application
- 2.4.1 Hospital
- 2.4.2 Clinic
- 2.5 Infantile Spasms Therapeutics Consumption by Application
- 2.5.1 Global Infantile Spasms Therapeutics Consumption Market Share by Application (2014-2019)
- 2.5.2 Global Infantile Spasms Therapeutics Value and Market Share by Application (2014-2019)
- 2.5.3 Global Infantile Spasms Therapeutics Sale Price by Application (2014-2019)
3 Global Infantile Spasms Therapeutics by Players
- 3.1 Global Infantile Spasms Therapeutics Sales Market Share by Players
- 3.1.1 Global Infantile Spasms Therapeutics Sales by Players (2017-2019)
- 3.1.2 Global Infantile Spasms Therapeutics Sales Market Share by Players (2017-2019)
- 3.2 Global Infantile Spasms Therapeutics Revenue Market Share by Players
- 3.2.1 Global Infantile Spasms Therapeutics Revenue by Players (2017-2019)
- 3.2.2 Global Infantile Spasms Therapeutics Revenue Market Share by Players (2017-2019)
- 3.3 Global Infantile Spasms Therapeutics Sale Price by Players
- 3.4 Global Infantile Spasms Therapeutics Manufacturing Base Distribution, Sales Area, Product Types by Players
- 3.4.1 Global Infantile Spasms Therapeutics Manufacturing Base Distribution and Sales Area by Players
- 3.4.2 Players Infantile Spasms Therapeutics Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 Infantile Spasms Therapeutics by Regions
- 4.1 Infantile Spasms Therapeutics by Regions
- 4.1.1 Global Infantile Spasms Therapeutics Consumption by Regions
- 4.1.2 Global Infantile Spasms Therapeutics Value by Regions
- 4.2 Americas Infantile Spasms Therapeutics Consumption Growth
- 4.3 APAC Infantile Spasms Therapeutics Consumption Growth
- 4.4 Europe Infantile Spasms Therapeutics Consumption Growth
- 4.5 Middle East & Africa Infantile Spasms Therapeutics Consumption Growth
5 Americas
- 5.1 Americas Infantile Spasms Therapeutics Consumption by Countries
- 5.1.1 Americas Infantile Spasms Therapeutics Consumption by Countries (2014-2019)
- 5.1.2 Americas Infantile Spasms Therapeutics Value by Countries (2014-2019)
- 5.2 Americas Infantile Spasms Therapeutics Consumption by Type
- 5.3 Americas Infantile Spasms Therapeutics Consumption by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Infantile Spasms Therapeutics Consumption by Countries
- 6.1.1 APAC Infantile Spasms Therapeutics Consumption by Countries (2014-2019)
- 6.1.2 APAC Infantile Spasms Therapeutics Value by Countries (2014-2019)
- 6.2 APAC Infantile Spasms Therapeutics Consumption by Type
- 6.3 APAC Infantile Spasms Therapeutics Consumption by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Infantile Spasms Therapeutics by Countries
- 7.1.1 Europe Infantile Spasms Therapeutics Consumption by Countries (2014-2019)
- 7.1.2 Europe Infantile Spasms Therapeutics Value by Countries (2014-2019)
- 7.2 Europe Infantile Spasms Therapeutics Consumption by Type
- 7.3 Europe Infantile Spasms Therapeutics Consumption by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Infantile Spasms Therapeutics by Countries
- 8.1.1 Middle East & Africa Infantile Spasms Therapeutics Consumption by Countries (2014-2019)
- 8.1.2 Middle East & Africa Infantile Spasms Therapeutics Value by Countries (2014-2019)
- 8.2 Middle East & Africa Infantile Spasms Therapeutics Consumption by Type
- 8.3 Middle East & Africa Infantile Spasms Therapeutics Consumption by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Marketing, Distributors and Customer
- 10.1 Sales Channel
- 10.1.1 Direct Channels
- 10.1.2 Indirect Channels
- 10.2 Infantile Spasms Therapeutics Distributors
- 10.3 Infantile Spasms Therapeutics Customer
11 Global Infantile Spasms Therapeutics Market Forecast
- 11.1 Global Infantile Spasms Therapeutics Consumption Forecast (2019-2024)
- 11.2 Global Infantile Spasms Therapeutics Forecast by Regions
- 11.2.1 Global Infantile Spasms Therapeutics Forecast by Regions (2019-2024)
- 11.2.2 Global Infantile Spasms Therapeutics Value Forecast by Regions (2019-2024)
- 11.2.3 Americas Consumption Forecast
- 11.2.4 APAC Consumption Forecast
- 11.2.5 Europe Consumption Forecast
- 11.2.6 Middle East & Africa Consumption Forecast
- 11.3 Americas Forecast by Countries
- 11.3.1 United States Market Forecast
- 11.3.2 Canada Market Forecast
- 11.3.3 Mexico Market Forecast
- 11.3.4 Brazil Market Forecast
- 11.4 APAC Forecast by Countries
- 11.4.1 China Market Forecast
- 11.4.2 Japan Market Forecast
- 11.4.3 Korea Market Forecast
- 11.4.4 Southeast Asia Market Forecast
- 11.4.5 India Market Forecast
- 11.4.6 Australia Market Forecast
- 11.5 Europe Forecast by Countries
- 11.5.1 Germany Market Forecast
- 11.5.2 France Market Forecast
- 11.5.3 UK Market Forecast
- 11.5.4 Italy Market Forecast
- 11.5.5 Russia Market Forecast
- 11.5.6 Spain Market Forecast
- 11.6 Middle East & Africa Forecast by Countries
- 11.6.1 Egypt Market Forecast
- 11.6.2 South Africa Market Forecast
- 11.6.3 Israel Market Forecast
- 11.6.4 Turkey Market Forecast
- 11.6.5 GCC Countries Market Forecast
- 11.7 Global Infantile Spasms Therapeutics Forecast by Type
- 11.8 Global Infantile Spasms Therapeutics Forecast by Application
12 Key Players Analysis
- 12.1 Mallinckrodt
- 12.1.1 Company Details
- 12.1.2 Infantile Spasms Therapeutics Product Offered
- 12.1.3 Mallinckrodt Infantile Spasms Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.1.4 Main Business Overview
- 12.1.5 Mallinckrodt News
- 12.2 H. Lundbeck
- 12.2.1 Company Details
- 12.2.2 Infantile Spasms Therapeutics Product Offered
- 12.2.3 H. Lundbeck Infantile Spasms Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.2.4 Main Business Overview
- 12.2.5 H. Lundbeck News
- 12.3 Insys Therapeutics
- 12.3.1 Company Details
- 12.3.2 Infantile Spasms Therapeutics Product Offered
- 12.3.3 Insys Therapeutics Infantile Spasms Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.3.4 Main Business Overview
- 12.3.5 Insys Therapeutics News
- 12.4 Orphelia Pharma
- 12.4.1 Company Details
- 12.4.2 Infantile Spasms Therapeutics Product Offered
- 12.4.3 Orphelia Pharma Infantile Spasms Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.4.4 Main Business Overview
- 12.4.5 Orphelia Pharma News
- 12.5 Valerion Therapeutics
- 12.5.1 Company Details
- 12.5.2 Infantile Spasms Therapeutics Product Offered
- 12.5.3 Valerion Therapeutics Infantile Spasms Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.5.4 Main Business Overview
- 12.5.5 Valerion Therapeutics News
- 12.6 Catalyst Pharmaceuticals
- 12.6.1 Company Details
- 12.6.2 Infantile Spasms Therapeutics Product Offered
- 12.6.3 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.6.4 Main Business Overview
- 12.6.5 Catalyst Pharmaceuticals News
- 12.7 Anavex Life Sciences
- 12.7.1 Company Details
- 12.7.2 Infantile Spasms Therapeutics Product Offered
- 12.7.3 Anavex Life Sciences Infantile Spasms Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.7.4 Main Business Overview
- 12.7.5 Anavex Life Sciences News
- 12.8 Retrophin
- 12.8.1 Company Details
- 12.8.2 Infantile Spasms Therapeutics Product Offered
- 12.8.3 Retrophin Infantile Spasms Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.8.4 Main Business Overview
- 12.8.5 Retrophin News
- 12.9 GW Pharmaceuticals
- 12.9.1 Company Details
- 12.9.2 Infantile Spasms Therapeutics Product Offered
- 12.9.3 GW Pharmaceuticals Infantile Spasms Therapeutics Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.9.4 Main Business Overview
- 12.9.5 GW Pharmaceuticals News
13 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Infantile Spasms Therapeutics . Industry analysis & Market Report on Infantile Spasms Therapeutics is a syndicated market report, published as Global Infantile Spasms Therapeutics Market Growth 2019-2024. It is complete Research Study and Industry Analysis of Infantile Spasms Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
